Global Fund press release
14 April 2026 — The United States and the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) announced an expanded commitment to scale up access to long-acting lenacapavir (LEN) for HIV PrEP, aiming to reach an additional 1 million people over the next three years. Building on the original commitment, this brings the total joint ambition to 3 million people reached with LEN through 2028.
This new milestone comes as countries begin rolling out LEN, marking a major step toward expanding access to a new generation of HIV prevention tools. Initial deliveries have reached nine African countries: Eswatini, Kenya, Lesotho, Mozambique, Nigeria, South Africa, Uganda, Zambia and Zimbabwe.
As of today, Eswatini, Kenya, Lesotho, Nigeria, Zambia, and Zimbabwe have started their rollouts of LEN with the other early adopters commencing soon. Early program data indicate that uptake is particularly strong among priority populations, including pregnant and breastfeeding women, adolescent girls and young women, and people accessing PrEP for the first time – highlighting LEN’s potential to reach those not previously accessing prevention. Data continue to be collected and consolidated as programs scale up across countries.
Building on this momentum, the Global Fund has also extended support for LEN PrEP introduction to 12 additional countries: Benin, Botswana, Dominican Republic, Fiji, Georgia, Haiti, Honduras, Indonesia, Morocco, Papua New Guinea, Rwanda and Thailand – reflecting strong and growing global demand for long-acting HIV prevention options.
Read the full press release here.
SEE ALSO:
- U.S. Department of State press release: United States-led partnership to provide an additional one million people with landmark American HIV drug lenacapavir to help end mother-to-child HIV transmission
- Gilead Sciences press release: PEPFAR and the Global Fund make additional investment in Gilead’s lenacapavir for HIV prevention to further expand access
- UNAIDS welcomes expanded rollout of HIV prevention medicine and calls for urgent action to ensure equitable and affordable global access
- Three million is a step forward, but not enough: AVAC and Access Bridge call for accelerated ambition and action to expand access to lenacapavir for PrEP
- Médecins Sans Frontières statement: Gilead announcement does not address why people can’t access groundbreaking HIV prevention medicine: Gilead must immediately do more to increase people’s access to lenacapavir
- Health Policy Watch: One million more people to get HIV ‘miracle’ drug lenacapavir as US, Global Fund expand access
Source : Global Fund
Related HIV and Co-Infections News
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
-
AVAC: Abrupt shutdown of US global health supply chain raises risks for HIV, TB and malaria programs
-
EL PAÍS: US aid cuts collapse Malawi’s LGBTQ+ health services as volunteers scramble to fill the void
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.